Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

syngenta australia pty ltd - trinexapac-ethyl - emulsifiable concentrate - trinexapac-ethyl cyclohexanediones active 250.0 g/l - herbicide - poppy | ryegrass seed crop | sugar cane | inter-row spraying | ratoon sugar cane | sugarcane - increase commercial cane sugar (ccs) | increase seed yield | modify alkaloid ratio | commercial cane sugar percenta | improved seed set | improving the percentage of th

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

grow choice pty ltd - diquat present as diquat dibromide; paraquat present as paraquat dichloride - suspension concentrate - diquat present as diquat dibromide pyridine-bipyridyl active 115.0 g/l; paraquat present as paraquat dichloride pyridine-bipyridyl active 135.0 g/l - herbicide - avocado | canola - see label | chickpea - see label | clover grass pasture - refer to label | cotton - refer to label | custard - african turnip weed | annual grass weed | annual ground cherry | annual pasture | annual ryegrass | annual weeds | annual weeds - see label | australian bindweed | australian bluebell - w. stricta | awnless barnyard grass | ball mustard | barley grass | barnyard or water grass | bathurst burr | bedstraw | bellvine | bifora, carrot weed or bird's eye | bindweed | blackberry nightshade | bladder ketmia | blue top - ageratum/heliotropium spp. | boggabri weed | broadleaf weeds | broadleaf weeds and grasses | brome grass | buffel grass | calopo | caltrop or yellow vine | capeweed | caustic weed | charlock | climbing buckwheat | columbus grass | common heliotrope | common storksbill | common vetch or tares | corn gromwell, ironweed or sheepweed | cowvine | cudweed | deadnettle | desiccation aid | erodium spp. | fat hen | fireweed | fleabane | fumitory | general weed control - see label | giant or black pigweed | grass - seed set | green summer grass | guinea grass | hamil grass | horehound | increase content of pas

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

wsd agribusiness pty ltd - phosphorus minimum; phosphorus maximum; nitrogen; boron; cobalt; copper; iron; iodine; potassium; magnesium; manganese; molybdenum; selenium; zinc - oral solution/suspension - phosphorus minimum ungrouped active 14000.0 mg/l; phosphorus maximum ungrouped active 15800.0 mg/l; nitrogen gas active 4300.0 mg/l; boron mineral-boron active 9.0 mg/l; cobalt mineral-cobalt active 350.0 mg/l; copper mineral-copper active 160.0 mg/l; iron mineral-iron active 170.0 mg/l; iodine mineral-iodine active 160.0 mg/l; potassium mineral-potassium active 22000.0 mg/l; magnesium mineral-magnesium active 2600.0 mg/l; manganese mineral-manganese active 320.0 mg/l; molybdenum mineral-molybdenum active 41.0 mg/l; selenium mineral-selenium active 43.0 mg/l; zinc mineral-zinc active 94.0 mg/l - nutrition & metabolism - cattle | sheep | beef | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | ewe | heifer | h - promote animal growth | feed conversion | finishing | growth promotion | growth rate | liveweight gain

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: hyprolose; lactose monohydrate; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; purified talc - olmesartan-myl is indicated for the treatment of hypertension.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - olmesartan medoxomil, quantity: 20 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hyprolose; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; purified talc - olmesartan-myl is indicated for the treatment of hypertension.

United States - English - NLM (National Library of Medicine)

paddock laboratories, llc - colistimethate sodium (unii: xw0e5ys77g) (colistimethate - unii:dl2r53p963) - colistin 150 mg in 2 ml

United States - English - NLM (National Library of Medicine)

international laboratories, llc - benazepril hydrochloride (unii: n1sn99t69t) (benazeprilat - unii:jrm708l703) - benazepril hydrochloride 20 mg - benazepril hydrochloride tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from

United States - English - NLM (National Library of Medicine)

ohm laboratories inc. - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - valsartan 40 mg - valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients six years of age and older. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. there are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmhg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). these considerations may guide selection of therapy. valsartan tablets may be used alone or in combination with other antihypertensive agents. additional pediatric use information is approved for novartis pharmaceuticals corporation's diovan (valsartan) tablets. however, due to novartis pharmaceuticals corporation's marketing exclusivity rights, this drug product is not labeled with that information. valsartan tablets are indicated to reduce the risk of hospitalization for heart failure in adult patients with heart failure (nyha class ii-iv). there is no evidence that valsartan tablets provide added benefits when it is used with an adequate dose of an angiotensin converting enzyme (ace) inhibitor [see clinical studies ( 14.2)]. in clinically stable adult patients with left ventricular failure or left ventricular dysfunction following myocardial infarction, valsartan tablets are indicated to reduce the risk of cardiovascular mortality [see clinical studies ( 14.3)]. do not use in patients with known hypersensitivity to any component. do not coadminister aliskiren with valsartan tablets in patients with diabetes [see drug interactions ( 7.3)] . risk summary valsartan tablets can cause fetal harm when administered to a pregnant woman. use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. published reports include cases of anhydramnios and oligohydramnios in pregnant women treated with valsartan (see clinical considerations ). when pregnancy is detected, consider alternative drug treatment and discontinue valsartan tablets as soon as possible. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. clinical considerations disease-associated maternal and/or embryo/fetal risk hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage). hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. pregnant women with hypertension should be carefully monitored and managed accordingly. fetal/neonatal adverse reactions oligohydramnios in pregnant women who use drugs affecting the renin-angiotensin system in the second and third trimesters of pregnancy can result in the following: reduced fetal renal function leading to anuria and renal failure, fetal lung hypoplasia, skeletal deformations, including skull hypoplasia, hypotension and death. in the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. in patients taking valsartan tablets during pregnancy, perform serial ultrasound examinations to assess the intra-amniotic environment. fetal testing may be appropriate, based on the week of gestation. patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. if oligohydramnios is observed, consider alternative drug treatment. closely observe neonates with histories of in utero exposure to valsartan tablets for hypotension, oliguria, and hyperkalemia. in neonates with a history of in utero exposure to valsartan tablets, if oliguria or hypotension occurs, support blood pressure and renal perfusion. exchange transfusions or dialysis may be required as a means of reversing hypotension and replacing renal function. data animal data no teratogenic effects were observed when valsartan was administered to pregnant mice and rats at oral doses of up to 600 mg/kg/day (9 and 18 times the maximum recommended human dose (mrhd) on a mg/m 2 basis) and to pregnant rabbits at oral doses of up to 10 mg/kg/day. in rats, oral valsartan administered at maternally toxic doses (600 mg/kg/day) during organogenesis or late gestation and lactation, resulted in decreased fetal and pup weight, pup survival and delayed developmental milestones. in rabbits administered maternally toxic doses of 5 and 10 mg/kg/day, fetotoxicity was observed. risk summary there is no information regarding the presence of valsartan tablets in human milk, the effects on the breastfed infant, or the effects on milk production. valsartan tablets are present in rat milk. because of the potential for serious adverse reactions in breastfed infants from exposure to valsartan, advise a nursing woman that breastfeeding is not recommended during treatment with valsartan tablets. data valsartan was detected in the milk of lactating rats 15 minutes after oral administration of a 3 mg/kg dose. the antihypertensive effects of valsartan tablets have been evaluated in a clinical study in pediatric patients from 6-16 years of age [see clinical studies ( 14.1)] . the pharmacokinetics of valsartan tablets have been evaluated in pediatric patients 1 to 16 years of age [see clinical pharmacology ( 12.3)] . the adverse experience profile of valsartan tablets was similar to that described for adults [see adverse reactions ( 6.1)] . in children and adolescents with hypertension where underlying renal abnormalities may be more common, renal function and serum potassium should be closely monitored as clinically indicated. use of valsartan tablets is not recommended in children less than 1 year of age [see nonclinical toxicology ( 13.2)] . it is not known whether post-natal use of valsartan, before maturation of renal function is complete, has a long-term deleterious effect on the kidney. no data are available in pediatric patients either undergoing dialysis or with a glomerular filtration rate <30 ml/min/1.73 m 2 . additional pediatric use information is approved for novartis pharmaceuticals corporation's diovan (valsartan) tablets. however, due to novartis pharmaceuticals corporation's marketing exclusivity rights, this drug product is not labeled with that information. in the controlled clinical trials of valsartan, 1,214 (36.2%) hypertensive patients treated with valsartan were ≥65 years and 265 (7.9%) were ≥75 years. no overall difference in the efficacy or safety of valsartan was observed in this patient population, but greater sensitivity of some older individuals cannot be ruled out. exposure [measured by area under the curve (auc)] to valsartan is higher by 70% in the elderly than in the young, however no dosage adjustment is necessary [see clinical pharmacology (12.3)] . of the 2,511 patients with heart failure randomized to valsartan in the valsartan heart failure trial, 45% (1,141) were 65 years of age or older. in the valsartan in acute myocardial infarction trial (valiant), 53% (2,596) of the 4,909 patients treated with valsartan and 51% (2,515) of the 4,885 patients treated with valsartan + captopril were 65 years of age or older. there were no notable differences in efficacy or safety between older and younger patients in either trial. safety and effectiveness of valsartan tablets in patients with severe renal impairment (glomerular filtration rate less than 30 ml/min/1.73 m 2 ) have not been established. no dose adjustment is required in patients with mild (glomerular filtration rate 60 to 90 ml/min/1.73 m 2 ) or moderate (glomerular filtration rate 30 to 60 ml/min/1.73 m 2 ) renal impairment. no dose adjustment is necessary for patients with mild-to-moderate liver disease. no dosing recommendations can be provided for patients with severe liver disease.

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc - benazepril hydrochloride (unii: n1sn99t69t) (benazeprilat - unii:jrm708l703) - benazepril hydrochloride 5 mg - benazepril hydrochloride tablets, usp are indicated for the treatment of hypertension. benazepril hydrochloride tablets may be used alone or in combination with thiazide diuretics. in using benazepril consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. available data are insufficient to show that benazepril hydrochloride tablets do not have a similar risk (see warnings). black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks. it should also be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. benazepril hydrochloride tablets are contraindicated in patients who are hypersensitive to this product or to any other ace inhibitor. benazepril hydrochloride tablets are also contraindicated in patients with

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - valsartan 320 mg - valsartan tablets, usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. there are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets, usp. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, d